TAILOR-PCI: Clopidogrel Genotyping Trial Narrowly Misses Endpoint TAILOR-PCI: Clopidogrel Genotyping Trial Narrowly Misses Endpoint

The trial missed its ambitious primary endpoint of a 50% reduction in cardiovascular events, but commentators felt nonetheless that it shows a clinical benefit and should change practice.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news